- For Print
- May 16, 2008
爱豆传媒. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that results from 16 clinical data abstracts about compounds in the company's oncology pipeline and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2008.
A wide variety of abstracts on Eisai marketed products and investigational compounds will showcase research focused on metastatic breast cancer, lung cancer, ovarian cancer, brain cancer, mesothelioma, pancreatic cancer, myelodysplastic syndromes and other types of cancer, as well as supportive care to aid those currently undergoing treatment for cancer.
“Eisai's commitment to oncology is clearly translating into substantial results in a growing pipeline,” said Haruo Naito. “Eisai's focus on becoming a global leader in oncology reflects our human health care mission to satisfy unmet medical needs and increase benefits to patients and their families.”
The following Eisai abstracts are accepted for presentation at this year's ASCO meeting.
*You can scroll to the left or right here
| Product | Abstract Details | Location Details |
|---|---|---|
MORAb-003 |
Exploratory Phase Ⅱ Efficacy Study of MORAb-003, a Monoclonal Antibody against Folate Receptor Alpha, in Platinum-Sensitive Ovarian Cancer in First Relapse Oral Presentation |
June 1, 2008 |
E7080 |
A phase I study of E7080 in patients with advanced malignancies Poster 3 |
May 31, 2008 Poster discussion |
E7080 |
Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors |
May 31, 2008 Poster discussion |
Cutaneous T-cell Lymphoma |
(Integrated analysis of three large Phase Ⅲ trials in CTCL) |
May 31, 2008 |
MORAb-003 |
A Phase I Study of MORAb-003, a Humanized Monoclonal Antibody Against Folate Receptor Alpha, in Advanced Epithelial Ovarian Cancer |
May 31, 2008 Poster discussion |
ALOXI® |
Palonosetron (PALO) for Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Prior to Stem Cell Transplant |
May 31, 2008 |
GCP Ⅱ Inhibitor |
Glutamate Carboxypeptidase Ⅱ Inhibition in Rat Models of Chemotherapy-induced Peripheral Neurotoxicity |
May 31, 2008 |
E7820 |
A phase I study of E7820 in combination with cetuximab in patients (pts) with advanced solid tumors |
June 1, 2008 |
MORAb-009 |
A Phase I Study of MORAb-009, a Monoclonal Antibody against Mesothelin, in Mesothelioma, Pancreatic, and Ovarian Cancer |
June 1, 2008 |
Eribulin Mesylate |
Phase Ⅱ Study of Eribulin Mesylate (E7389) in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracycline, Taxane, and Capecitabine Therapy |
June 2, 2008 |
Advanced Breast Cancer |
Oncologist and Patient Roles in Assessing Current and Future Treatment for Metastatic Breast Cancer: Results of an Observational Linguistic study |
June 2, 2008 |
DACOGEN® |
A Multicenter Phase Ⅱ Trial of the Decitabine Alternative 5-day Dosing Regimen: Analysis of Efficacy in Various Subgroups of Patients with Myelodysplastic Syndromes |
June 2, 2008 Poster discussion |
DACOGEN® |
Cytogenetic Responses to a 5-Day Dosing Schedule of Decitabine in Patients with Myelodysplastic Syndromes |
June 2, 2008 Poster discussion |
ALOXI® |
Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: Results of a Phase Ⅲ trial in Japanese patients (This study was conducted by Taiho Pharmaceutical Co., Ltd. in Japan with support from Helsinn Healthcare SA. Taiho owns the marketing rights in Japan for palonosetron HCl.) |
Accepted for publication only. |
ALOXI® |
Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV) |
Accepted for publication only. |
GLIADEL® Wafer |
Treatment of Adults with Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma with Surgery, Gliadel Wafers and Limited Field Radiation Plus Concomitant Temozolomide Followed by Adjuvant Temozolomide |
Accepted for publication only. |
Eisai began its oncology research program in 1987, discovering several small molecules that are in development as chemotherapeutic agents. In addition to its in-house oncology research and development (R&D) program, Eisai made three strategic acquisitions to establish a solid business infrastructure and enter the U.S. oncology market.
In October 2006, Eisai acquired four products mainly for the treatment of cutaneous T-cell lymphoma, as well as an oncology specialty sales force, from Ligand Pharmaceuticals. This provided Eisai with an initial commercial infrastructure for oncology products. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired MGI PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial capabilities, pipeline and product portfolio in oncology and supportive care.
Eisai is committed to addressing the unmet medical needs of patients with cancer and deliver novel treatment options that create hope with them.